Kyntra Bio (KYNB) Receivables (2014 - 2026)
Kyntra Bio (KYNB) posted Receivables of $9.0 million for Q1 2026, up 114.42% sequentially from $4.2 million in Q4 2025, and up 6049.66% YoY from $147000.0 in Q1 2025.
Kyntra Bio (KYNB) Receivables (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Receivables for 13 years, with the latest figure at $9.0 million in Q1 2026.
- Quarterly Receivables rose 6049.66% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 6049.66% YoY) and the FY2025 annual result came in at $9.5 million, down 67.22% from the prior year.
- Receivables improved to $9.0 million in Q1 2026 per KYNB's latest filing, from $4.2 million in the prior quarter.
- Over five years, Receivables peaked at $88.0 million in Q1 2022 and troughed at $136000.0 in Q2 2025.
- A 5-year average of $34.7 million and a median of $33.6 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2025 and 2026: Receivables plunged 99.78% in 2025, then jumped 6049.66% in 2026.
- Over 5 years, Receivables stood at $61.3 million in 2022, then sank by 45.14% to $33.6 million in 2023, then fell by 13.8% to $29.0 million in 2024, then sank by 85.45% to $4.2 million in 2025, then surged by 114.42% to $9.0 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $9.0 million, $4.2 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 347,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 347,000.00 |
| Mar 31, 2026 | 9.04 Mn |
| Dec 31, 2025 | 4.22 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 28.98 Mn |
| Sep 30, 2024 | 57.53 Mn |
| Jun 30, 2024 | 34.91 Mn |
| Mar 31, 2024 | 65.58 Mn |
| Dec 31, 2023 | 33.62 Mn |
| Sep 30, 2023 | 35.69 Mn |
| Jun 30, 2023 | 45.55 Mn |
| Mar 31, 2023 | 29.22 Mn |
| Dec 31, 2022 | 61.29 Mn |
| Sep 30, 2022 | 29.67 Mn |
| Jun 30, 2022 | 60.35 Mn |
| Mar 31, 2022 | 87.96 Mn |
| Dec 31, 2021 | 28.33 Mn |
| Sep 30, 2021 | 59.12 Mn |